{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"14","value":"161.2"},{"groupId":"OG001","spread":"15","value":"166.1"},{"groupId":"OG002","spread":"49","value":"180.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Cycle 1/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11","value":"182.6"},{"groupId":"OG001","spread":"27","value":"171.2"},{"groupId":"OG002","spread":"16","value":"151.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Cycle 1/Day15-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10","value":"165.5"},{"groupId":"OG001","spread":"22","value":"176.7"},{"groupId":"OG002","spread":"26","value":"171.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"title":"Cycle 2/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"185.0"},{"groupId":"OG001","spread":"27","value":"203.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 4/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG000","spread":"NA","value":"229.0"},{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG001","spread":"NA","value":"174.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 6/Day1-1 Hour/EOI"},{"categories":[{"measurements":[{"comment":"Geometric Coefficient of Variation was not estimable as there was only 1 participant analyzed.","groupId":"OG000","spread":"NA","value":"191.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"Cycle 10/Day1-1 Hour/EOI"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Cmax is maximum observed plasma concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 sub-cutaneous \\[SC\\] administered at weekly intervals, followed by 5 intra tumoral \\[IT\\] administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W. Phase 2 was not planned.","id":"OG000","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg + Avelumab"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus utomilumab 100 mg administered IV Q4W. Phase 2 was not planned.","id":"OG001","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + Utomilumab 100 mg"},{"description":"During Phase 1b participants with SCCHN received CMP-001 at 10 mg for an initial 7 doses (2 SC administered at weekly intervals, followed by 5 IT administered at weekly intervals) and then administered IT Q2W for all cohorts along with 10 mg/kg of avelumab administered IV Q2W all cohorts plus PF-04518600 at 0.3 mg/kg administered IV Q2W. Phase 2 was not planned.","id":"OG002","title":"Combination F Phase 1b SCCHN: CMP-001 10 mg Then Avelumab + PF-04518600 0.3 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who had received at least one dose of study drug and who had at least one of the PK concentrations of interest for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"1-hour post-infusion (i.e. at the end of infusion) on Days 1 and 15 of Cycle 1 (non-dosing); Day 1 of Cycles 2, 4, 6 and Cycle 10","title":"Maximum Observed Plasma Concentration (Cmax) of Avelumab in Combination F","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}